Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas

John P. Crown; Subhash Gulati; David J. Straus; Jonathan Kolitz; Robert Heelan; James O'Brien; Burton J. Lee; Carol Portlock; Joseph Bertino

doi:10.1007/BF00175086

Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV²) in relapsed and refractory lymphomas

John P. Crown, Subhash Gulati, David J. Straus, Jonathan Kolitz, Robert Heelan, James O'Brien, Burton J. Lee, Carol Portlock, Joseph Bertino

CINJ - Basic Research

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

As part of a program to develop less leukemogenic chemotherapy regimens for the treatment of favorable prognosis Hodgkin's disease, a phase I-II trial of mitoxantrone, etoposide, mitoguazone, and vinblastine was used to treat patients with relapsed and refractory malignant lymphoma and Hodgkin's disease. An over-all partial response rate of 41% was observed. Although useful responses were seen, the absence of complete remissions is disappointing.

Original language	English (US)
Pages (from-to)	185-186
Number of pages	2
Journal	Investigational New Drugs
Volume	9
Issue number	2
DOIs	https://doi.org/10.1007/BF00175086
State	Published - May 1 1991

All Science Journal Classification (ASJC) codes

Oncology
Pharmacology
Pharmacology (medical)

Keywords

etoposide
mitoguazone
mitoxantrone
relapsed/refractory lymphomas
vinblastine

Access to Document

10.1007/BF00175086

Fingerprint Dive into the research topics of 'Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV<sup>2</sup>) in relapsed and refractory lymphomas'. Together they form a unique fingerprint.

Cite this

@article{8821705287144a12a2e4870d303687db,

title = "Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas",

abstract = "As part of a program to develop less leukemogenic chemotherapy regimens for the treatment of favorable prognosis Hodgkin's disease, a phase I-II trial of mitoxantrone, etoposide, mitoguazone, and vinblastine was used to treat patients with relapsed and refractory malignant lymphoma and Hodgkin's disease. An over-all partial response rate of 41% was observed. Although useful responses were seen, the absence of complete remissions is disappointing.",

keywords = "etoposide, mitoguazone, mitoxantrone, relapsed/refractory lymphomas, vinblastine",

author = "Crown, {John P.} and Subhash Gulati and Straus, {David J.} and Jonathan Kolitz and Robert Heelan and James O'Brien and Lee, {Burton J.} and Carol Portlock and Joseph Bertino",

year = "1991",

month = may,

day = "1",

doi = "10.1007/BF00175086",

language = "English (US)",

volume = "9",

pages = "185--186",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "2",

}

Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV²) in relapsed and refractory lymphomas. / Crown, John P.; Gulati, Subhash; Straus, David J.; Kolitz, Jonathan; Heelan, Robert; O'Brien, James; Lee, Burton J.; Portlock, Carol; Bertino, Joseph.

In: Investigational New Drugs, Vol. 9, No. 2, 01.05.1991, p. 185-186.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Mitoxantrone, etoposide, mitoguazone and vinblastine chemotherapy (MV2) in relapsed and refractory lymphomas

AU - Crown, John P.

AU - Gulati, Subhash

AU - Straus, David J.

AU - Kolitz, Jonathan

AU - Heelan, Robert

AU - O'Brien, James

AU - Lee, Burton J.

AU - Portlock, Carol

AU - Bertino, Joseph

PY - 1991/5/1

Y1 - 1991/5/1

N2 - As part of a program to develop less leukemogenic chemotherapy regimens for the treatment of favorable prognosis Hodgkin's disease, a phase I-II trial of mitoxantrone, etoposide, mitoguazone, and vinblastine was used to treat patients with relapsed and refractory malignant lymphoma and Hodgkin's disease. An over-all partial response rate of 41% was observed. Although useful responses were seen, the absence of complete remissions is disappointing.

AB - As part of a program to develop less leukemogenic chemotherapy regimens for the treatment of favorable prognosis Hodgkin's disease, a phase I-II trial of mitoxantrone, etoposide, mitoguazone, and vinblastine was used to treat patients with relapsed and refractory malignant lymphoma and Hodgkin's disease. An over-all partial response rate of 41% was observed. Although useful responses were seen, the absence of complete remissions is disappointing.

KW - etoposide

KW - mitoguazone

KW - mitoxantrone

KW - relapsed/refractory lymphomas

KW - vinblastine

UR - http://www.scopus.com/inward/record.url?scp=0025818380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025818380&partnerID=8YFLogxK

U2 - 10.1007/BF00175086

DO - 10.1007/BF00175086

M3 - Article

C2 - 1874601

AN - SCOPUS:0025818380

VL - 9

SP - 185

EP - 186

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -